For research use only. Not for therapeutic Use.
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research[1].
| Catalog Number | I042203 |
| CAS Number | 1635395-25-3 |
| Purity | ≥95% |
| Reference | [1]. Claudia Giampietri, et al. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies. J Transl Med. 2022 Oct 12;20(1):467. |
